Keyphrases
Overall Survival
100%
Phase II Trial
100%
BRCA1, BRCA2
100%
Olaparib
100%
Olympia
100%
Germline Pathogenic Variant
100%
High-risk Early Breast Cancer
100%
Disease-free Survival
62%
Distant Metastasis-free Survival
62%
Invasive Disease
62%
Confidence Interval
50%
Interim Analysis
50%
Placebo Groups
50%
Placebo
37%
Early Breast Cancer
25%
Statistical Significance
25%
Safety Signal
25%
BRCA2
12%
Acute Myeloid Leukemia
12%
Myelodysplastic Syndrome
12%
High Risk
12%
Germ Cells
12%
Hormone Receptor-positive
12%
Randomized Double-blind
12%
Breast Cancer Susceptibility Gene 1 (BRCA1)
12%
Adjuvant Therapy
12%
Neoadjuvant Chemotherapy
12%
Radiation Therapy
12%
Endocrine Therapy
12%
Likely Pathogenic Variant
12%
Subset Analysis
12%
Surgery Therapy
12%
Adjuvant Surgery
12%
Hazard Ratio
12%
Neoadjuvant Radiation
12%
Human Epidermal Growth Factor Receptor 2-negative
12%
Poly(adenosine diphosphate-ribose) Polymerase inhibitor
12%
Medicine and Dentistry
Breast Cancer
100%
Disease Free Survival
100%
Overall Survival
100%
BRCA1
100%
Olaparib
100%
Germ Cell
100%
Placebo
70%
Interim Analysis
40%
Adjuvant Therapy
10%
Hormone Therapy
10%
Radiation Therapy
10%
Drug Therapy
10%
Acute Myeloid Leukemia
10%
Myelodysplastic Syndrome
10%
Malignant Neoplasm
10%
Hazard Ratio
10%
BRCA2
10%
Gamma Urogastrone
10%
Epidermal Growth Factor Receptor 2
10%
Neoadjuvant Chemotherapy
10%
Poly ADP Ribose Polymerase
10%
Hormone Receptor
10%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Breast Cancer
100%
Disease Free Survival
100%
Olaparib
100%
Placebo
70%
Chemotherapy
10%
Endocrine Therapy
10%
Malignant Neoplasm
10%
Epidermal Growth Factor Receptor 2
10%
Gamma Urogastrone
10%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
10%
Acute Myeloid Leukemia
10%
Hormone Receptor
10%
Myelodysplastic Syndrome
10%